A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.

Tufia C HaddadRui QinRuth LupuDaniel SateleMatthew EadensMatthew P GoetzCharles ErlichmanJulian Molina

Published in: Cancer chemotherapy and pharmacology (2017)

Cilengitide in combination with paclitaxel was well tolerated. Antitumor activity was observed. The recommended phase II dose is twice weekly cilengitide (2000 mg) with weekly paclitaxel (90 mg/m2). Further studies evaluating drugs that target this pathway are warranted.

Keyphrases

phase ii
clinical trial
open label
chemotherapy induced
study protocol